Two University of Missouri researchers have joined forces with an international pharmaceutical firm to develop a promising treatment for prostate cancer using gold nanoparticles.
Nanomedicine experts Kattesh Katti and Raghuraman Kannan of the School of Medicine and Shasun Pharmaceuticals Ltd. have formed a new company, Nanoparticle Biochem Inc. (NBI), to continue research and testing that could lead to the treatment’s use in humans.
“MU’s proactive support of our research has allowed Dr. Kannan and I to join Shasun in taking this important step toward helping cancer patients,” said Katti, a Curator’s Professor of radiology and physics. “This kind of culture has put MU on the map as a destination for world-class science that attracts international attention and investment.”
Reviewed 2013-02-18